Multiple Myeloma & Lymphoma Summit

Park City, UT US
May 19, 2023 to May 20, 2023

This CME-accredited activity “Multiple Myeloma & Lymphoma Summit” features leading experts in hematologic malignancies who will provide a comprehensive overview of current and emerging strategies for management of multiple myeloma, lymphoma, and Waldenström Macroglobulinemia. The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances in newly diagnosed and relapsed multiple myeloma and lymphomas with a focus on emerging immunotherapies, including but not limited to, CAR-T therapy and T-cell redirecting bispecific antibodies. Expert faculty will aim to place the role of different therapeutic agents in clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care.

Target Audience

  • Cancer care professionals
  • Practicing medical oncologists/hematologists
  • Radiation oncologists
  • Pathologists
  • Medical oncology and hematology fellows
  • Oncology nurses
  • Nurse practitioners
  • Physician assistants
  • Pharmacists

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Review strategies for induction, autologous transplantation, and maintenance therapy for patients with newly diagnosed multiple myeloma
  • Outline efficacy and toxicities of monoclonal antibodies, antibody drug conjugates, T-cell redirecting bispecific antibodies, and CAR-T for the treatment of patients with relapsed and refractory multiple myeloma
  • Review CAR-T, bispecific antibodies, and antibody drug conjugates in management of DLBCL patients
  • Apply an individualized treatment plan for patients with early/advanced stage cHL and T cell lymphomas 
  • List indications and toxicity profile of novel targeted agents in management of indolent lymphomas including CLL, FL, MCL
  • Review the indications for the treatment of Waldenström Macroglobulinemia and current therapeutic strategies
Course summary
Available credit: 
  • 6.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.50 Contact Hours.
Course opens: 
12/01/2022
Course expires: 
07/20/2023
Event starts: 
05/19/2023 - 5:00pm PDT
Event ends: 
05/20/2023 - 4:15pm PDT
Cost:
$200.00

Conference Chairs: Dr. Harsh Shah & Dr. Douglas Sborov

DAY 1 - May 19, 2023


Networking Meet & Greet: Downtown Park City, Location TBD

 

DAY 2 - May 20, 2023

 

07:00 AM - 07:45 AM          Breakfast, Exhibits, and registration


07:50 AM – 08:00 AM          Welcome remarks


08:00 AM - 09:15 AM         Session 1: Newly Diagnosed Multiple Myeloma: How Much and for How Long?

08:00 AM - 08:20 AM          Transplant Ineligible Disease: Is there a role for proteosome inhibitors

08:20 AM – 08:40 AM         The Role of Quadruplet Therapy for All Newly Diagnosed Patients

08:40 AM - 09:00 AM          Maintenance Therapy: Drug Choice and Duration of Treatment

09:00 AM - 09:15 AM          Case-based panel discussion


09:15 AM - 10:25 AM         Session 2: Relapsed and Refractory Multiple Myeloma and Emerging Immunotherapies

09:15 AM - 09:35 AM          What to Use and When: Drug Sequencing in Relapsed and Refractory Multiple Myeloma

09:35 AM - 09:55 AM          CAR-T and T-cell Redirecting Bispecific Antibodies in Multiple Myeloma

09:55 AM - 10:10 AM          New and Exciting Therapeutics: An ASH Update

10:10 AM - 10:30 AM          Case-based panel discussion


10:30 AM - 10:45 AM          Break & Exhibits


10:45 AM - 12:00 PM         Session 3: Management of patients with Indolent Lymphomas with immunotherapy and targeted agents

10:45 AM - 11:00 AM         Treatment Updates in Waldenström Macroglobulinemia - Dr. Amandeep Godara

11:00 AM - 11:15 AM          Frontline management of patients with CLL in the era of targeted agents - Dr. Deborah Stephens

11:15 AM - 11:30 AM          Updates in the management of patients with MCL in frontline and relapsed/refractory setting - Dr. Daniel Ermann

11:30 AM - 11:45 AM          Emerging role of immunotherapy and targeted agents in management of FL (including CAR T)

11:45 AM- 12:00 AM          Case-based panel discussion


12:00 PM - 01:30 PM          Lunch  & Exhibits


01:30 PM - 02:45 PM         Session 4: Management of patients with Aggressive Lymphomas with immunotherapy and targeted agents

01:30 PM - 01:50 PM          Frontline treatment of patients with DLBCL - Dr. Lindsey Fitzgerald

01:50 PM - 02:10 PM          CAR-T updates in DLBCL

02:10 PM - 02:30 PM          The role of other immunotherapies (Bi-specifics, ADCs, ASCT) in DLBCL - Dr. Dipenkumar Modi

02:30 PM - 02:45 PM          Case-based panel discussion


02:45 PM - 04:15 PM         Session 5: Management of Hodgkin Lymphoma and T cell Lymphomas

02:45 PM - 03:05 PM          Frontline Management of patients with early stage and Advanced cHL - Dr. Boyu Hu

03:05 PM - 03:25 PM          Immunotherapy in relapsed/refractory cHL - Dr. Harsh Shah

03:25 PM - 03:45 PM          Updates in cutaneous T cell Lymphomas - Dr. Ahmad Halwani

03:45 PM - 04:15 PM          Case-based panel discussion


04:15 PM - 04:20 PM          Concluding remarks

DoubleTree by Hilton Park City – The Yarrow
1800 Park Ave
Park City, UT 84060
United States

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

 

Speaker(s)

Daniel Ermann, Medical Doctor

has no relevant financial relationships to disclose at this time.

Amandeep Godara, MD

has no relevant financial relationships to disclose at this time.

Boyu Hu

has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Other) with OncLive;.
has a financial relationship (Grant Or Contract) with Celgene/BMS;.
has a financial relationship (Grant Or Contract) with Repare Therapeutics;.
has a financial relationship (Other) with ADC Therapeutics;.
has a financial relationship (Other) with Novartis;.
has a financial relationship (Other) with TG Therapeutics;.
has a financial relationship (Other) with Bristol Meyer Squibb;.
has a financial relationship (Grant Or Contract) with Morphosys Ag;.
has a financial relationship (Grant Or Contract) with Caribou Biosciences;.
has a financial relationship (Other) with MJH Life Sciences;.
has a financial relationship (Grant Or Contract) with CRISPR Therapeutics;.

Available Credit

  • 6.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.50 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$200.00
Please login or register to take this course.

REGISTRATION FEES 

Physicians (non-industry) - $200

Non-physician HCP (non-industry) - $75

Industry representatives - $850

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is cancelled six weeks before the conference.
  • No refunds will be issued if registration is cancelled after that date.  

No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post tests as well as course evaluations.